325 mg Clinical Data
In a single-center, randomized, active-controlled, single-blind, triple crossover PK and PD study of antiplatelet activity over 3 days, in obese patients with type 2 diabetes.1
Time to Complete
Antiplatelet
Effect
In this study, VAZALORE 325 mg achieved 99% inhibition of thromboxane B2 generation significantly faster (12.5 hours) than enteric coated aspirin 325 mg (48.2 hours) (p<0.0001).1
This study design cannot provide data on cardiovascular outcomes.
Study population: obese patients with type 2 diabetes

Plasma
Acetylsalicylic
Acid (ASA) Concentration Versus Time
AUC = area under curve
This study design cannot provide data on cardiovascular outcomes.
Study population: obese patients with type 2 diabetes

Inhibition of TXB2
GENERATION by 72 hours
This study design cannot provide data on cardiovascular outcomes.
Study population: obese patients with type 2 diabetes

Upper GI Injury: Plain Aspirin vs VAZALORE2
Upper GI Damage Comparison
• 47% lower risk of erosions or ulcers (NNT=5)
• 71% lower risk of ulcers (NNT=8)
ITT = intent to treat; NNT = number needed to treat

References:
- Bhatt DL, Grosser T, Dong J-F, et al. Enteric coating and aspirin nonresponsiveness in patients with type 2 diabetes mellitus. J Am Coll Cardiol. 2017;69(6):603-612.
- Cryer B, Bhatt DL, Lanza FL, Dong JF, Lichtenberger LM, Marathi UK. Low-dose aspirin-induced ulceration is attenuated by aspirin–phosphatidylcholine: a randomized clinical trial. Am J Gastroenterol. 2011;106(2):272-277.